ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 04, 2023 18:00 JST
Source:
BioMed X Institute
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies
After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
HEIDELBERG, Germany, Apr 04, 2023 - (ACN Newswire) - BioMed X, an independent biomedical research institute, announces the start of its new research project - "New Strategies to Enhance the Immunogenicity of Tumors" - in collaboration with Merck. The focus of this new research group will be to develop novel approaches for enhancing tumor immunogenicity to broaden the population of patients who could benefit from cancer immunotherapy.
"What if we could overcome the immunosuppressive microenvironment of solid tumors with a novel targeted approach?" asks Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute. "This call for application is inviting original research proposals that explore new ways to enhance the immunogenicity of tumors and thus boost the efficacy of immune checkpoint inhibitors," explains Dr. Tidona.
A high mutational burden, as well as aberrant mRNA splicing, are sources of neoantigens: unique antigens presented by tumor cells capable of eliciting an effective anti-tumor immune response. The most recently completed BioMed X project was also a Merck collaboration investigating RNA splicing patterns in cancer. "Using a new bioinformatic approach, we were able to query splicing variants that are unique to certain cancers," said Dr. Alexandra Duarte, former group leader at the BioMed X Institute. "Such splicing abnormalities can shape the complex pathophysiology of cancer cells, including through the expression of immunogenic neoantigens," added Dr. Duarte, now a Senior Scientist in the Department of mRNA Cancer Immunotherapies of Prof. Dr. Ugur Sahin at HI-TRON in Mainz, Germany.
The new project launched today, marking the tenth joint research group between the two partners, expands this line of research by targeting tumor-specific DNA Damage Repair (DDR) mechanisms or exploiting tumor-intrinsic DDR defects to increase the tumor mutational burden and immunogenicity. Researchers who are interested in becoming part of this new BioMed X research team in Heidelberg are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at
https://career.bio.mx/call/2023-BMX-C01
before May 28, 2023.
About BioMed X
BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
SOURCE: BioMed X Institute
Source: BioMed X Institute
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Podium for TOYOTA GAZOO Racing in Le Mans thriller
Jun 17, 2024 11:34 JST
Fujitsu begins impact investing to address the challenge of solving social issues and to achieve a sustainable society
Jun 17, 2024 10:14 JST
NTT DATA and DENSO Sign a Basic Agreement on Strategic Partnership for Software
Jun 13, 2024 18:01 JST
Honda and MC to Establish New Company, ALTNA Co., Ltd.
Jun 13, 2024 17:18 JST
Honda to Begin Sales of New N-VAN e: Commercial-use Mini-EV in Japan
Jun 13, 2024 16:04 JST
JCB and iMago Launch "Chikazuite-Check" Project to Provide a New Buying Experience
Jun 13, 2024 14:00 JST
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India
Jun 12, 2024 11:00 JST
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jun 10, 2024 18:50 JST
Yuki Tsunoda to Continue Competing in F1 for the 2025 Season with VISA Cash App RB Formula One Team
Jun 10, 2024 12:37 JST
Honda Advances Hydrogen Strategy with Production Launch of Fuel Cell Electric Vehicle in Ohio
Jun 07, 2024 18:29 JST
Le Mans awaits TOYOTA GAZOO Racing
Jun 07, 2024 16:56 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of New LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY GREEN in Shimonoseki
Jun 07, 2024 16:38 JST
MHIEC Receives Order to Rebuild Waste-to-Energy Plant in Hodogaya Ward, Yokohama
Jun 06, 2024 19:34 JST
MHI Thermal Systems Launches New "TEK Series" of Electric-Driven Transport Refrigeration Units for Small and Mid-Size Trucks
Jun 06, 2024 12:20 JST
MHI and EGAT sign MoU to Introduce Hydrogen Large Gas Turbine Co-firing Technology in Thailand to Achieve Net Zero Goals
Jun 05, 2024 19:09 JST
Mitsubishi Shipbuilding Receives Additional Order for 2 Units of LNG Fuel Gas Supply System (FGSS)
Jun 05, 2024 18:14 JST
NEC announces external appointment of executive personnel
Jun 05, 2024 17:43 JST
JCB collaborates with Singapore's Mandai Wildlife Group to promote wildlife park visitorship
Jun 05, 2024 12:00 JST
Hitachi and Microsoft Enter Milestone Agreement to Accelerate Business and Social Innovation with Generative AI
Jun 04, 2024 14:45 JST
Japan Energy Summit & Exhibition 2024 Unites Global Leaders to Propel Asia's Emergence in Climate Leadership
Jun 04, 2024 11:09 JST
More Latest Release >>
Related Release
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
May 28 2024 18:00 JST
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
May 16 2024 22:00 JST
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
February 06 2024 23:00 JST
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
December 22 2023 09:00 JST
BioMed X Launches a New Call for Application in Autoimmune Disease Research
November 07 2023 19:00 JST
BioMed X and AbbVie Start New Research Project in the USA
November 01 2023 07:00 JST
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus
April 27 2023 20:00 JST
More Press release >>